[18F]PSMA-1007 PET/CT解读标准的诊断影响:与CT和骨扫描的前瞻性比较
这项前瞻性研究纳入284例不同疾病阶段的患者,评估[¹⁸F]PSMA-1007 PET/CT不同阳性阈值(PSMA-RADS分类、PSMA表达评分、SUVmax)的诊断效能,并与CT和骨扫描比较。以PSMA-RADS-4为阳性阈值时,PET/CT灵敏度78.5%、特异度95.3%,诊断效能优于其他标准,且灵敏度和准确率均高于CT和骨扫描。
要点
- 以PSMA-RADS-4为阳性阈值,[¹⁸F]PSMA-1007 PET/CT灵敏度78.5%、特异度95.3%,为最优解读标准。
- PSMA-RADS-4阈值下,PET/CT灵敏度高于CT(81.3% vs 48.6%)和骨扫描(84.5% vs 65.7%)。
- PSMA-RADS-3病灶真阳性率69.7%,显著低于PSMA-RADS-4病灶的96.7%。
核心结论
- PSMA-RADS-4是[¹⁸F]PSMA-1007 PET/CT的最佳阳性阈值,诊断效能优于CT和骨扫描,支持其用于标准化图像解读。
研究设计与样本
- 前瞻性研究纳入284例不同疾病阶段患者,均接受[¹⁸F]PSMA-1007 PET/CT检查,共分析771个病灶。
- 基于PSMA-RADS分类、PSMA表达评分和SUVmax设定不同阳性阈值,评估诊断效能并与CT和骨扫描比较。
主要发现
- 以PSMA-RADS-4为阳性阈值,[¹⁸F]PSMA-1007 PET/CT灵敏度78.5%、特异度95.3%。
- PSMA-RADS-3阈值灵敏度98.4%、特异度58.8%;PSMA表达评分2灵敏度52.2%、特异度99.3%;SUVmax cutoff 5.7灵敏度72.6%、特异度85.8%。
- PSMA-RADS-4阈值下,PET/CT灵敏度高于CT(81.3% vs 48.6%)和骨扫描(84.5% vs 65.7%),准确率亦更高(83.2% vs 56.2%和87.6% vs 74.5%)。
- PSMA-RADS-3病灶真阳性率69.7%,显著低于PSMA-RADS-4病灶的96.7%。
关键数值与推荐
- PSMA-RADS-4为最佳阳性阈值:灵敏度78.5%、特异度95.3%。
- PSMA-RADS-3阈值灵敏度98.4%、特异度58.8%。
- PSMA表达评分2阈值灵敏度52.2%、特异度99.3%;SUVmax cutoff 5.7灵敏度72.6%、特异度85.8%。
- PSMA-RADS-3病灶真阳性率69.7%,PSMA-RADS-4病灶真阳性率96.7%。
临床怎么用
- 临床解读[¹⁸F]PSMA-1007 PET/CT时推荐以PSMA-RADS-4作为阳性阈值,以平衡灵敏度和特异度。
- PSMA-RADS-4阈值下PET/CT对病灶的检出灵敏度优于CT和骨扫描,可作为标准化解读依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The PSMA Reporting and Data System (PSMA-RADS) has been proposed to standardize the interpretation of PSMA-PET. However, its diagnostic performance has not been fully validated. This study aimed to determine the optimal interpretation criteria for PSMA-PET and to compare its diagnostic performance with conventional imaging. METHODS: This prospective study enrolled 284 patients across various disease stages who underwent [¹⁸F]PSMA-1007 PET/CT. Diagnostic performance was evaluated using different positivity thresholds based on PSMA-RADS categories, PSMA-expression scores, and SUVmax, and was compared with that of CT and bone scan (BS). True-positive rates were summarized across PSMA-RADS categories. RESULTS: A total of 771 lesions were analyzed. PSMA-RADS demonstrated superior diagnostic performance compared with other interpretation criteria. Using PSMA-RADS-4 as the positivity threshold, [¹⁸F]PSMA-1007 PET/CT achieved a sensitivity of 78.5% and a specificity of 95.3%. PSMA-RADS-3 increased sensitivity to 98.4% but reduced specificity to 58.8%. PSMA-expression score 2 yielded a sensitivity of 52.2% and a specificity of 99.3%, whereas SUVmax cutoff of 5.7 yielded a sensitivity of 72.6% and a specificity of 85.8%. When PSMA-RADS-4 was used as the positivity threshold, PET/CT showed higher sensitivity than CT (81.3% vs. 48.6%) and BS (84.5% vs. 65.7%), as well as higher accuracy (83.2% vs. 56.2% and 87.6% vs. 74.5%, respectively). The true-positive rate of PSMA-RADS-3 lesions was 69.7%, which was substantially lower than that of PSMA-RADS-4 lesions (96.7%). CONCLUSION: PSMA-RADS-4 represents an optimal positivity threshold for [¹⁸F]PSMA-1007 PET/CT, providing superior diagnostic performance compared with CT and BS and supporting its clinical utility for standardized image interpretation.
引用
- Liu Y, Hatano K, Uemura M, et al. Diagnostic impact of interpretation criteria for [18F]PSMA-1007 PET/CT: Prospective comparison with CT and bone scan. Eur J Nucl Med Mol Imaging. 2026. PMID: 42168644. doi:10.1007/s00259-026-07931-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。